ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,0804
-0,12%
Bitcoin
69.416,71
0,12%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Coya Therapeutics Inc (COYA)

  7. Coya Therapeutics Inc (COYA) News

COYA

Coya Therapeutics (COYA)

Coya Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:COYA
DatumZeitQuelleÜberschriftSymbolFirma
06/06/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
06/06/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
05/06/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
03/06/202414h15Business WireCoya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in NeurologyNASDAQ:COYACoya Therapeutics Inc
28/05/202414h15Business WireCoya Therapeutics Announces Inclusion in the MSCI USA Micro Cap IndexNASDAQ:COYACoya Therapeutics Inc
22/05/202414h15Business WireCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s DiseaseNASDAQ:COYACoya Therapeutics Inc
20/05/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
20/05/202414h15Business WireCoya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)NASDAQ:COYACoya Therapeutics Inc
09/05/202422h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COYACoya Therapeutics Inc
09/05/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
09/05/202422h10Business WireCoya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
08/05/202423h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
26/04/202414h15Business WireCoya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
22/04/202414h15Business WireCoya Therapeutics to Participate in the Mizuho Neuroscience SummitNASDAQ:COYACoya Therapeutics Inc
18/04/202414h15Business WireCoya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:COYACoya Therapeutics Inc
08/04/202414h15Business WireCoya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
19/03/202413h15Business WireCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
12/03/202414h00Business WireCoya Therapeutics to Participate in BTIG Fireside DiscussionNASDAQ:COYACoya Therapeutics Inc
12/03/202413h00Business WireCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
06/03/202414h15Business WireCoya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
06/03/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
29/02/202414h15Business WireCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
22/02/202414h15Business WireCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
21/02/202414h15Business WireCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”NASDAQ:COYACoya Therapeutics Inc
13/02/202414h15Business WireCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesNASDAQ:COYACoya Therapeutics Inc
03/02/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
03/02/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
29/01/202414h15Business WireCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
20/01/202400h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
20/01/202400h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:COYA

Kürzlich von Ihnen besucht

BITMOT
2665867
Eu Mfa Ukr Next Gen Fx 4...
BOV
D2PZ34M
Dominos Pizza
NASDAQ
AAYATXX
Barclays Bank Plc Point ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten